Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Istiratumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CARRIE
- Sponsors Merrimack Pharmaceuticals
- 30 Jul 2020 This trial is discontinued in UK (Global End Date: 12 Jun 2018), according to European Clinical Trials Database record.
- 01 Jan 2020 Results published in the Annals of Oncology
- 25 Jun 2018 According to a Merrimack Pharmaceuticals media release, Merrimack plans to present the complete data from this Phase 2 study at an upcoming medical oncology meeting.